Rates of Malignancy by The Bethesda System for Reporting Thyroid Cytopathology Category 3 and Category 4 Thyroid Nodules
Öz
Aim: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is employed to evaluate the cytopathology of thyroid nodules. The nodules reported as categories 3 and 4 constitute risk of malignancy at varying rates. This study aims to document the amount of actual malignancy rates in TBSRTC category 3 and 4 thyroid nodules.
Materials and Methods: Patients having thyroid nodules with reported Bethesda category 3 and category 4 results on fine needle aspiration biopsy who subsequently underwent thyroidectomy between January 2013 and December 2018 were retrospectively analyzed.
Results: Seventy-two patients and 72 nodules were included in our study. The Bethesda category 3 group consisted of 40 patients and 40 nodules. The histopathologic result was reported as benign in 23 (57,5%) patients and malignant in 17 (42,5%) patients. The Bethesda category 4 group covered the remaining 32 patients and 32 nodules. Histopathologic results were reported as benign in 12 patients (37,5%) and malignant in 20 patients (62,5%).
Conclusion: Bethesda category 3 and 4 nodules bear varying rates of malignancy risk, and this rate increases with the presence of additional incidentally detected malignancies.
Anahtar Kelimeler
Kaynakça
- References: 1.Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Journal of the American Society of Cytopathology. 2017 Nov;6(6):217–22.
- 2.Ryu YJ, Jung YS, Yoon HC, Hwang MJ, Shin SH, Cho JS, et al. Atypia of undetermined significance on thyroid fine needle aspiration: surgical outcome and risk factors for malignancy. Ann Surg Treat Res. 2014;86(3):109-14.
- 3.Altın F, Paksoy M. What Should Be Considered in Bethesda III Thyroid Nodules When Prefering Hemitioidectomy or Total Thyroidectomy. Haseki. 2020 Jun 17;58(3):293–300.
- 4.Mosca L, Silva LFF da, Carneiro PC, Chacon DA, Araujo-Neto VJF de, Araujo-Filho VJF de, et al. Malignancy rates for Bethesda III subcategories in thyroid fine needle aspiration biopsy (FNAB). Clinics. 2018;73:e370. No grants or support resources were used. The writers do not have any conflicts of interest. All authors declared their contribution to the study at all stages. All authors took part in the study design and approve the final version of the manuscript.
- 5.Sarkis LM, Norlen O, Aniss A, Watson N, Delbridge LW, Sidhu SB, et al. The Australian experience with the Bethesda classification system for thyroid fine needle aspiration biopsies. Pathology. 2014 Dec;46(7):592–5.
- 6.Alshaikh S, Harb Z, Aljufairi E, Almahari SA. Classification of thyroid fine-needle aspiration cytology into Bethesda categories: An institutional experience and review of the literature. Cytojournal. Published online Feb 16 2018.doi: 10.4103/cytojournal.cytojournal_32_17.
- 7.Williams BA, Bullock MJ, Trites JR, Taylor SM, Hart RD. Rates of thyroid malignancy by FNA diagnostic category. J of Otolaryngol - Head & Neck Surg. 2013 Dec;42(1):61.
Tiroid Sitopatolojisini Raporlamak için Bethesda Sistemi'ne Göre Kategori 3 ve Kategori 4 Tiroid Nodüllerinin Malignite Oranları
Öz
Amaç: Tiroid nodüllerinin sitopatolojisini değerlendirmek için kullanılan Tiroid Sitopatoloji Raporlaması için Bethesda Systemi’ne (TSRBS) gore kategori 3 ve kategori 4 olarak raporlanan nodüller değişik oranlarda malignite riskleri taşır. Bu çalışmanın amacı TSRBS kategori 3 ve 4 tiroid nodüllerinde malignite oranlarını saptayıp değerlendirmektir.
Gereç veYöntemler: Ocak 2013- Aralık 2018 tarihleri arasında ince iğne aspirasyon sonuçları Bethesda kategori 3 ve kategori 4 olan, sonrasında tiroidektomi uygulanan hastalar retrospektif olarak değerlendirildi.
Bulgular: Çalışmamıza 72 hasta, 72 nodül dahil edildi. Bethesda kategori 3 grubunda 40 hasta,-40 nodül mevcuttu. Histopatoloji sonucu 23 (%57,5) hastada benign, 17 (%42,5) hastada malign olarak raporlandı. Bethesda kategori 4 grubunda 32 hasta-32 nodül mevcuttu. Histopatoloji sonucu 12 hastada (%37,5) benign, 20 hastada (% 62,5) malign olarak raporlandı.
Sonuç: Bethesda kategori 3 ve 4 nodülleri değişik oranlarda malignite riski taşır ve insidental olarak saptanan maligniteler ile de bu oran artar.
Anahtar Kelimeler
Kaynakça
- References: 1.Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Journal of the American Society of Cytopathology. 2017 Nov;6(6):217–22.
- 2.Ryu YJ, Jung YS, Yoon HC, Hwang MJ, Shin SH, Cho JS, et al. Atypia of undetermined significance on thyroid fine needle aspiration: surgical outcome and risk factors for malignancy. Ann Surg Treat Res. 2014;86(3):109-14.
- 3.Altın F, Paksoy M. What Should Be Considered in Bethesda III Thyroid Nodules When Prefering Hemitioidectomy or Total Thyroidectomy. Haseki. 2020 Jun 17;58(3):293–300.
- 4.Mosca L, Silva LFF da, Carneiro PC, Chacon DA, Araujo-Neto VJF de, Araujo-Filho VJF de, et al. Malignancy rates for Bethesda III subcategories in thyroid fine needle aspiration biopsy (FNAB). Clinics. 2018;73:e370. No grants or support resources were used. The writers do not have any conflicts of interest. All authors declared their contribution to the study at all stages. All authors took part in the study design and approve the final version of the manuscript.
- 5.Sarkis LM, Norlen O, Aniss A, Watson N, Delbridge LW, Sidhu SB, et al. The Australian experience with the Bethesda classification system for thyroid fine needle aspiration biopsies. Pathology. 2014 Dec;46(7):592–5.
- 6.Alshaikh S, Harb Z, Aljufairi E, Almahari SA. Classification of thyroid fine-needle aspiration cytology into Bethesda categories: An institutional experience and review of the literature. Cytojournal. Published online Feb 16 2018.doi: 10.4103/cytojournal.cytojournal_32_17.
- 7.Williams BA, Bullock MJ, Trites JR, Taylor SM, Hart RD. Rates of thyroid malignancy by FNA diagnostic category. J of Otolaryngol - Head & Neck Surg. 2013 Dec;42(1):61.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Cerrahi Onkoloji |
| Bölüm | Araştırma Makaleleri |
| Yazarlar | |
| Yayımlanma Tarihi | 25 Eylül 2023 |
| Gönderilme Tarihi | 13 Mart 2023 |
| Yayımlandığı Sayı | Yıl 2023 Cilt: 2 Sayı: 3 |
Kaynak Göster
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.